NCT01990092Unknown不适用
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Nutritional Benefits of Metanx® in Subjects With Diabetic Peripheral Neuropathy
适应症
试验速览
- 阶段
- 不适用
- 发起方
- Pamlab, Inc.
- 入组人数
- 238
- 试验地点
- 50
- 主要终点
- Change in plasma methylmalonic acid (MMA) levels
研究概览
简要总结
The objectives of the MEDIAN study are to evaluate the short-term and long-term safety and nutritional benefits of Metanx® versus placebo in subjects with mild to moderate diabetic peripheral neuropathy (DPN). Short-term effects will be evaluated during the first 16 weeks of treatment, and long-term effects will be evaluated over the duration of a 48 week treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 25 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be male or female between 25 and 80 years of age, inclusive, at the time of consent
- •Have a diagnosis of diabetes mellitus Type 2 as defined by the American Diabetes Association and on stable therapy as defined per the investigator's opinion for at least 1 month before the Screening Visit.
- •Have a diagnosis of DPN established at least 6 months but not greater than 7 years prior to Screening
- •If receiving DPN-related medication, doses must be stable for at least 6 weeks and should be taking only one of the following medications compliant with Exclusion Criterion 7:
- •Alpha-2-delta ligand [e.g., pregabalin (Lyrica) or gabapentin (Neurontin)
- •Anticonvulsant [e.g., carbamazepine, topiramate (Topamax), valproic acid (Depakote) or lamotrigine (Lamictal)]
- •Serotonin-norepinephrine Reuptake Inhibitor (SNRI) [e.g., duloxetine (Cymbalta) or venlafaxine (Effexor)]
- •Tricyclic antidepressant (TCA) [e.g., amitriptyline, nortriptyline, imipramine, and desipramine (Norpramin, Pertofrane)]
- •Have a score between 3 and 6, inclusive, on the Michigan Neuropathy Screening Instrument (MNSI) Part b
- •Have a minimum score of 6 on the NTSS-6 at Screening
- •Have negative urinalysis for drugs of abuse, such as amphetamines, barbiturates, cannabinoids, cocaine, or opiates
- •Have a negative urine pregnancy test at Screening if female and of childbearing potential
- •If female, must be either of nonchildbearing potential (surgically sterile or 2 years postmenopausal) or agree to use two methods of effective contraception such as hormonal contraception, intrauterine device or other mechanical contraception device, or condom plus spermicide during the subject's participation
- •If male, must be surgically sterile or agree to use two methods of effective contraception such as condom plus spermicide during the subject's participation
- •Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
- •Have provided written authorization for use and disclosure of protected health information
排除标准
- •Be pregnant or lactating
- •Have a history of amputation, skin ulceration, and/or active Charcot of either foot
- •Have a history of previous surgery involving the spine or lower extremity, with residual symptoms of pain or difficulty with movement
- •Have Crohn's disease or a history of any type of bariatric surgery or any surgical resection of all or part of the stomach, duodenum, jejunum, and/or ileum. (Previous surgical resections of the colon that spared the stomach, duodenum, jejunum and ileum are allowed.)
- •Have a history of surgery or hospitalization within 2 months prior to Screening or planned hospitalization at any time during the study
- •Be taking systemic corticosteroids within 2 months prior to Screening, opiates or tramadol hydrochloride within 6 weeks prior to Screening, and/or immunosuppressives, or receiving radiotherapy within 6 months prior to Screening
- •Be taking more than one anticonvulsant, serotonin-norepinephrine reuptake inhibitor (SNRI), or tricyclic antidepressant (TCA)
- •Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot, history of claudication, or history of lower extremity vascular bypass surgery or angioplasty
- •Have circulating glycated hemoglobin (HbA1c) exceeding 11% at Screening
- •Have an estimated glomerular filtration rate (eGFR) less than or equal to 40 ml/min using the Modification of Diet in Renal Disease (MDRD) formula at Screening or have end-stage renal disorder requiring hemodialysis
- •Have uncontrolled hypertension defined as sustained systolic blood pressure (SBP) greater than 200 mmHg or diastolic blood pressure (DBP) greater than 110 mmHg at screening
- •Have lung disease (uncontrolled asthma or shortness of breath) within 2 months prior to Screening
- •Use of any of the following supplements within 6 weeks before Screening: evening primrose oil, vitamin B12 injection, greater than 10 mg of vitamin B6, or greater than 800 µg of folate
- •Have previously failed two or more prior therapies for painful DPN
- •Currently abusing alcohol or drugs or have a history of such abuse within the past 3 years. (Alcohol abuse is defined as more than 2 drink units per day for women and more than 3 drink units per day for men. One drink unit is defined as 1.5 oz [45 mL] of distilled spirits, 5 oz [150 mL] of wine, or 12 oz [360 mL] of beer.)
- •Have any nondiabetic cause of peripheral neuropathy
- •Have a history of documented lumbar nerve entrapment or symptoms suggestive of a lumbar nerve entrapment
- •Have a history of systemic lupus erythematosis, rheumatoid arthritis, Sjögren's syndrome, or mixed connective tissue disease
- •If receiving thyroid replacement therapy, should be on a stable dose for at least 6 weeks prior to Screening
- •Have a history of a positive HIV test or active Hepatitis B or C infection.
- •Have a history or presence of malignancy within 10 years prior to Screening except for basal or squamous cell carcinoma of the skin. Records to be submitted to Pamlab for review and approval to randomize.
- •Have prior use of or intolerance to Metanx® or any of its active ingredients
- •Have been dosed or used a medical device in another investigational trial within 60 days prior to Screening.
- •Have any clinically significant existing medical, psychiatric, or nonmedical condition that in the opinion of the investigator places the subject at undue risk, prevents compliance with the study protocol, or potentially jeopardizes the quality of the data to be generated
结局指标
主要结局
Change in plasma methylmalonic acid (MMA) levels
时间窗: 16 weeks
次要结局
- Change in neuropathic disability as measured by the Michigan Neuropathy Screening Instrument part B(48 weeks)
- Change in neuropathic symptoms as measured by the Neuropathy Total Symptom Score-6questionnaire(NTSS-6)(16 weeks)
- Change in neuropathic symptoms as measured by the Neuropathy Total Symptom Score-6 questionnaire (NTSS-6)(48 weeks)
- Change in plasma 5-methyltetrahydrofolate levels(16 weeks)
- Change in plasma vitamin B6 levels(16 weeks)
- Change in plasma vitamin B12 levels(16 weeks)
- Change in urine microalbumin/creatinine ratio(48 weeks)
- Change in epidermal nerve fiber density(48 weeks)
研究者
研究点 (50)
Loading locations...
相似试验
已完成
4 期
Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)COPDNCT01488019Dey1,071
已完成
4 期
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study USGastroesophageal Reflux DiseaseNCT00660660AstraZeneca276
已完成
不适用
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV InfectionHIV InfectionsNCT00002290Glaxo Wellcome
已完成
2 期
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)Acute Spinal Cord InjuryNCT01502631Daiichi Sankyo65
已完成
2 期
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown LinesModerate to Severe Glabellar Frown LinesNCT03806933Merz Aesthetics GmbH241